Drugs that contain Carbidopa; Levodopa
1. Dhivy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439613 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11819485 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
Market Authorisation Date: 12 November, 2021
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Method of treating parkinson's di...
Dosage: TABLET;ORAL
DHIVY family patents
2. Rytary patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7094427 | IMPAX LABS INC | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May, 2022
(1 year, 11 months ago) | |
| US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 07, 2018 |
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Method of p...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RYTARY family patents